Icotrokinra is currently being developed through a licensing and collaboration agreement between Protagonist and J&J.

Intraclass biologic switching had better short-term efficacy in psoriasis, but both intraclass and interclass switching were effective long-term.

Findings published in JAMA Dermatology suggest that the use of immune checkpoint inhibitors may double psoriasis risk for ...

Thena Natural Wellness's Best Skin Healing Cream For Eczema, Psoriasis, Rosacea, Dermatitis, Heat Rash, Hives & More No more ...

Patients with psoriasis have a higher risk for synovitis on imaging than healthy individuals, according to a systematic ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Researchers have established that smoking tobacco has a high likelihood of increasing the risk of relapse in patients ...

New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...